These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15651764)

  • 1. Clinically validated genotype analysis.
    Flandre P
    Antivir Ther; 2004 Dec; 9(6):1037-8; author reply 1038-9. PubMed ID: 15651764
    [No Abstract]   [Full Text] [Related]  

  • 2. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection and significance of minority quasispecies of drug-resistant HIV-1.
    Metzner KJ
    J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-1 genotypic drug-resistance interpretation algorithms need to include hypersusceptibility-associated mutations.
    Wang K; Samudrala R; Mittler JE
    J Infect Dis; 2004 Dec; 190(11):2055-6; author reply 2056. PubMed ID: 15529272
    [No Abstract]   [Full Text] [Related]  

  • 5. Algorithms for the interpretation of HIV-1 genotypic drug resistance information.
    Vercauteren J; Vandamme AM
    Antiviral Res; 2006 Sep; 71(2-3):335-42. PubMed ID: 16782210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance.
    Wei X; Youngpairoj AS; Garrido C; Zahonero N; Corral A; de Mendoza C; Heneine W; Johnson JA; Garcia-Lerma JG
    J Clin Virol; 2011 Feb; 50(2):148-52. PubMed ID: 21130027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV drug resistance tests: an update on methods for calculating phenotypic fold change from a viral genotype.
    Bellosillo NA; Bacheler L; Villacian J
    Clin Infect Dis; 2009 Mar; 48(5):687; author reply 687. PubMed ID: 19191661
    [No Abstract]   [Full Text] [Related]  

  • 8. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 drug resistance in variants from the female genital tract and plasma.
    Kemal KS; Burger H; Mayers D; Anastos K; Foley B; Kitchen C; Huggins P; Schroeder T; Picchio G; Back S; Gao W; Meyer WA; Weiser B
    J Infect Dis; 2007 Feb; 195(4):535-45. PubMed ID: 17230413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the drug resistance situation among recently infected HIV-1 patients in Dehong].
    Wang MJ; Duan S; Xiang LF; Yang YC; Tu YQ; Wang JB; Yao J; Qi J; Jiang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Sep; 29(9):905-8. PubMed ID: 19173856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An updated guide to genotype interpretation.
    MacArthur RD
    AIDS Read; 2004 May; 14(5):256-8, 261-4, 266. PubMed ID: 15199855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Resistance development. Are drug resistant HIV-1 minorities relevant for therapeutic success?].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():15. PubMed ID: 19024909
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
    Gallant JE
    AIDS Read; 2006 Oct; 16(10):556-9. PubMed ID: 17096474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
    Miller MD; Margot N; McColl D; Cheng AK
    AIDS; 2007 Jan; 21(2):265-6. PubMed ID: 17197831
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of Viroseq-HIV version 2 for HIV drug resistance.
    Mukaide M; Sugiura W; Matuda M; Usuku S; Noguchi Y; Suzuki K; Kawata K; Ito A; Sagara H; Yamada K; Kondo M; Imai M
    Jpn J Infect Dis; 2000 Oct; 53(5):203-5. PubMed ID: 11135705
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prevalence of antiretroviral drug genotypic resistance among HIV patients in Cuenca, Spain].
    Rodriguez-Escudero MJ; Prada de Medio E; Rosa Herranz C; Martinez Medina MC; Franquelo Gutierrez R
    Rev Esp Quimioter; 2007 Jun; 20(2):203-5. PubMed ID: 17893756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical significance of viral fitness.
    Geretti AM
    J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessments of HIV drug resistance mutations in resource-limited settings.
    Jordan MR
    Clin Infect Dis; 2011 Apr; 52(8):1058-60. PubMed ID: 21460325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.